• Rhizen announces presentation of interim data from its Tenalisib + Romidepsin combination study in patients with relapsed/refractory peripheral and cutaneous T cell lymphoma.
• The Tenalisib and Romidepsin combination was well tolerated with overall safety profile comparable to that of individual agents.
• The combination has showed encouraging signals of efficacy in patients who have failed multiple lines of prior therapies
• The company expects that the final results of the study will support a pivotal trial for the combination and plans to seek FDA feedback on its strategy once the full results are available.
LA CHAUX DU FONDS, Switzerland-Sunday 6 December 2020 [ AETOS Wire ]
(BUSINESS WIRE)-- Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced presentation of the interim results of a Phase I/II combination study of Tenalisib with Romidepsin for relapsed/refract
Read more »